Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Adjuvant treatment of colon cancer: three vs six months of FOLFOX/CAPOX

Alberto F. Sobrero • 18 May 2020
ASCO 2020
Colorectal Cancer Gastrointestinal Cancer 5-fluorouracil Capecitabine Oxaliplatin
MOSAIC

Alberto F. Sobrero, MD, Ospedale San Martino, Genova, Italy, discusses the final results from the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) collaboration study. This study evaluated overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based therapy for patients with stage III colon cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Alberto F. Sobrero

3:24
COVID-19 & the management of cancer patients
Alberto F. Sobrero • 3 Jun 2020
4:15
Colon cancer: a new prognostic and predictive tool
Alberto F. Sobrero • 18 May 2020

Related Videos

0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals